Tenaya Therapeutics Inc   (TNYA)
Other Ticker:  
Price: $5.8400 $0.15 2.636%
Day's High: $5.88 Week Perf: 10.19 %
Day's Low: $ 5.23 30 Day Perf: 39.38 %
Volume (M): 899 52 Wk High: $ 8.09
Volume (M$): $ 5,248 52 Wk Avg: $3.98
Open: $5.46 52 Wk Low: $1.66

 Market Capitalization (Millions $) 432
 Shares Outstanding (Millions) 74
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -128
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 1

Tenaya Therapeutics Inc
Tenaya Therapeutics Inc is a biotechnology company focused on developing novel treatments for cardiovascular diseases. The company aims to leverage advancements in regenerative medicine and gene therapy to address unmet medical needs in the field. Tenaya Therapeutics is working on various innovative approaches, including reprogramming the body's own cells to regenerate damaged heart tissue and developing gene therapies that can reverse or prevent cardiovascular diseases. The company's ultimate goal is to improve outcomes and quality of life for patients suffering from heart conditions.

   Company Address: 171 Oyster Point Boulevard South San Francisco 94080 CA
   Company Phone Number: 825-6990   Stock Exchange / Ticker: NASDAQ TNYA
   TNYA is expected to report next financial results on March 07, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Unleashing the Potential: HDAC6 Inhibition for Heart Failure with Preserved Ejection Fraction

Published Mon, Feb 26 2024 1:30 PM UTC

In recent years, heart failure with preserved ejection fraction (HFpEF) has emerged as a significant health challenge, with limited treatment options available. However, a recent publication in Nature Communications by Tenaya Therapeutics has shed light on a potential breakthrough. Their preclinical data presents promising findings on the use of HDAC6 inhibitors in the treat...

Financing Agreement

Tenaya Therapeutics Prices Underwritten Offering, Garnering Strong Investor Interest for Advancements in Heart Disease Research

Published Thu, Feb 8 2024 1:00 PM UTC

Tenaya Therapeutics Announces Successful Pricing of Underwritten Offering, Garnering Significant Investment Interest
South San Francisco-based biotechnology company, Tenaya Therapeutics, made a significant announcement today regarding the successful pricing of its underwritten offering. The company, known for its mission to discover and develop potentially curative thera...

Tenaya Therapeutics Inc

Biotech & Pharmaceuticals Company's Operating Deficit Sees Progress, But Still Lingers at $-31.298 Million

The Biotechnology & Pharmaceuticals sector has been a beacon of hope for investors seeking significant returns. However, while industry leaders continue to flourish, lesser-known companies like Tenaya Therapeutics Inc (TNYA) are struggling to make their mark. The recent financial results announced by TNYA reveal a worrisome operating deficit and a mediocre bottom-line, signaling a bearish outlook for the company.
Operating Deficit and Stagnant Progress
TNYA recently disclosed an operating deficit of $-30.92 million for the third quarter of 2023, surpassing its performance in the same period the previous year. This revelation is especially alarming, considering the company's current stage of development. As a company operating in the progress stage, TNYA should be displaying signs of growth and improvement. Unfortunately, the opposite seems to be true.

Tenaya Therapeutics Inc

Tenaya Therapeutics Inc. Faces Major Setback with $-35 Million Operating Deficit in Q2 2023, Shareholders Hopeful for New Revenue Streams

The Biotechnology & Pharmaceuticals industry has been closely analyzing the latest financial figures from the second quarter of 2023. Notably, there has been a significant operating deficit of $-35.104 million reported by one company within this sector. What's particularly interesting is that this company has not disclosed any revenue for this reporting period, which spans from April to June 30, 2023.
Shareholders in this entity are eagerly awaiting the arrival of new revenue streams in the near future. They are not relying on the current productivity improvement at the Biotechnology & Pharmaceuticals company, as they anticipate additional sources of income to boost the organization's financial standing. The fact that the company recorded a net loss of $-33.269 million in the second quarter of 2023, compared to $-28.397 million in the same period last year, is not entirely surprising given the lack of reported revenue.

Tenaya Therapeutics Inc

Tenaya Therapeutics Inc Struggles with Growing Expenses, Records $124 Million Net Loss

Tenaya Therapeutics Inc Records Cumulative Net Loss of $-124 Million During 12 Months Ending in Q1 2023
Tenaya Therapeutics Inc, the leading biotechnology and pharmaceuticals company, has recorded a cumulative net loss of $-124 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -56.59%, which is lower than the industry average.
The latest earning report has revealed that 84 other companies in the biotechnology and pharmaceutical industry had a higher return on equity. However, Tenaya Therapeutics Inc's overall ROE ranking has advanced in Q1 2023 to 2268 from the total ROE ranking in the fourth quarter of 2022 at 3575.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com